Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
William Valentine, Kirsi Norrbacka & Kristina Secnik Boye. (2022) Evaluating the Impact of Therapy on Quality of Life in Type 2 Diabetes: A Literature Review of Utilities Associated with Treatment-Related Attributes. Patient Related Outcome Measures 13, pages 97-111.
Read now
Read now
Kristina S Boye, Shraddha Shinde, Tessa Kennedy-Martin, Susan Robinson & Vivian T Thieu. (2022) Weight Change and the Association with Adherence and Persistence to Diabetes Therapy: A Narrative Review. Patient Preference and Adherence 16, pages 23-39.
Read now
Read now
Kristina S. Boye, Louis S. Matza, Katie D. Stewart, Haylee Andrews, Timothy A. Howell, Adam Stefanski, Karen G. Malley, K. Jack Ishak & Laura Fernández Landó. (2022) Health state utilities associated with weight loss in type 2 diabetes and obesity. Journal of Medical Economics 25:1, pages 14-25.
Read now
Read now
Carlos Morillas, Rosa Feliciano, Pablo Fernández Catalina, Carla Ponte, Marta Botella, João Rodrigues, Enric Esmatjes, Javier Lafita, Luis Lizán, Ignacio Llorente, Cristóbal Morales, Jorge Navarro-Pérez, Domingo Orozco-Beltran, Silvia Paz, Antonio Ramirez de Arellano, Cristina Cardoso & Maribel Tribaldos Causadias. (2015) Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference and Adherence 9, pages 1443-1458.
Read now
Read now
Aude Roborel de Climens, Kaan Tunceli, Benoit Arnould, Nicola Germain, Kristy Iglay, Josephine Norquist & Kimberly G. Brodovicz. (2015) Review of patient-reported outcome instruments measuring health-related quality of life and satisfaction in patients with type 2 diabetes treated with oral therapy. Current Medical Research and Opinion 31:4, pages 643-665.
Read now
Read now
S. Lane, A. R. Levy, J. Mukherjee, J. Sambrook & H. Tildesley. (2014) The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Current Medical Research and Opinion 30:7, pages 1267-1273.
Read now
Read now
Articles from other publishers (12)
Kristina S. Boye, Jérémie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici, Maria Yu, Hélène Sapin, Annabel Barrett, Bruno Guerci, Francesco Giorgino, Martin Füchtenbusch & Luis‐Emilio García‐Pérez. (2023)
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (
TROPHIES
): Final patient‐reported outcomes at 24 months
. Diabetes, Obesity and Metabolism 25:12, pages 3453-3464.
Crossref
Crossref
Kristina S. Boye, Hélène Sapin, Luis-Emilio García-Pérez, Myriam Rosilio, Marco Orsini Federici, Elke Heitmann, Heike Jung, Ulrich Aigner, Bruno Guerci, Francesco Giorgino & Kirsi Norrbacka. (2020) The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes. Diabetes Therapy 11:10, pages 2383-2399.
Crossref
Crossref
Enrico Torre, Giacomo Matteo Bruno, Sergio Di Matteo, Chiara Martinotti, Maria Chiara Valentino, Luigi Carlo Bottaro & Giorgio Lorenzo Colombo. (2020) Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Health Services Insights 13, pages 117863292092998.
Crossref
Crossref
Mahdi Toroski, Abbas Kebriaeezadeh, Alireza Esteghamati, Ali Kazemi Karyani, Hadi Abbasian & Shekoufeh Nikfar. (2019) Patient and physician preferences for type 2 diabetes medications: a systematic review. Journal of Diabetes & Metabolic Disorders 18:2, pages 643-656.
Crossref
Crossref
Hussam Aly Sayed, Tawfik Mohammed Ali Ghabra, Marwan Abdulrahman Mohammed B, Misbahuddin Mohammed R & Samy Saleh Eid. (2019) Is Urinary Calprotectin a Useful Tool to Detect the Therapeutic Control of Type II Diabetes?. International Journal of Pharmacology 15:2, pages 295-300.
Crossref
Crossref
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado & Kristina S. Boye. (2017) Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics 39:11, pages 2284-2295.
Crossref
Crossref
Amélie Beaudet, John Clegg, Per-Olof Thuresson, Adam Lloyd & Phil McEwan. (2014) Review of Utility Values for Economic Modeling in Type 2 Diabetes. Value in Health 17:4, pages 462-470.
Crossref
Crossref
Christine Poulos, Juan Marcos González, Lauren J. Lee, Kristin S. Boye, F. Reed Johnson, Jay P. Bae & Mark A. Deeg. (2013) Physician Preferences for Extra-Glycemic Effects of Type 2 Diabetes Treatments. Diabetes Therapy 4:2, pages 443-459.
Crossref
Crossref
Scott Doyle, Andrew Lloyd, Lee Moore, Joshua Ray & Alastair Gray. (2012) A Systematic Review and Critical Assessment of Health State Utilities. PharmacoEconomics 30:12, pages 1133-1143.
Crossref
Crossref
Susan Grandy, Kathleen M. Fox & Debbra D. Bazata. (2012) Association of Self-Reported Weight Change and Quality of Life, and Exercise and Weight Management Behaviors Among Adults with Type 2 Diabetes Mellitus: The SHIELD Study. Cardiology Research and Practice 2012, pages 1-7.
Crossref
Crossref
Ana Vieta, Xavier Badia & José A. Sacristán. (2011) A Systematic Review of Patient-Reported and Economic Outcomes: Value to Stakeholders in the Decision-Making Process in Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics 33:9, pages 1225-1245.
Crossref
Crossref
Robert A. Arbuckle, Louise Humphrey, Kawitha Vardeva, Bhakti Arondekar, Muriel Danten-Viala, Jane A. Scott & Frank J. Snoek. (2009) Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress. Value in Health 12:8, pages 1168-1175.
Crossref
Crossref